Novo Nordisk released encouraging phase 2 results for amycretin in type 2 diabetes, the first evaluation of this dual GLP-1 and amylin agonist in this population. Both the oral and subcutaneous formulations produced dose-dependent reductions in HbA1c and body weight, with up to 14.5 percent weight loss and no plateau at 36 weeks. A high proportion of patients reached HbA1c targets below 7 percent and 6.5 percent, and the safety profile was consistent with other incretin and amylin-based therapies.
The strength of the data has led Novo Nordisk to expand amycretin into a pivotal phase 3 diabetes program in 2026. The findings also reinforce the company’s commitment to providing treatment options that meet different patient needs through both oral and injectable formulations.
Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer, noted that the results reflect continued investment in promising metabolic biology. He also acknowledged the EVOKE and EVOKE+ Alzheimer’s trials, which did not meet their primary endpoint, noting that progress often comes through high-risk, high-learning research.
Lange thanked investigators, trial teams, and the patients and families who took part in both programs, emphasizing their essential role in advancing treatments for chronic diseases.
The amycretin results point to meaningful progress in metabolic disease, and the EVOKE findings add valuable knowledge in an area where continued research remains essential. Together, they show how progress can come from both strong results and the knowledge gained when outcomes differ from expectations.
Sources
